← All trials
NCT07152821
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2025
- Primary completion
- Dec 31, 2028
- Completion date
- Jun 30, 2029
- First posted
- Sep 3, 2025
- Last posted
- Nov 20, 2025
- Enrollment
- 834
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Canadian Cancer Trials GroupLead sponsor
- Australasian Gastro-Intestinal Trials GroupCollaborator
- Agenus Inc.Collaborator
- British Columbia Cancer AgencyOfficial
- UNICANCERCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.